Eli Lilly’s Brenipatide Trial Adds Quiet Optionality in Schizophrenia

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.

The RENEW-Scz-1 trial is a Phase 2 study from Eli Lilly and Company that tests an add-on drug called brenipatide for adults with schizophrenia. The goal is to see if adding brenipatide to usual care improves symptoms and remains safe over time, which could support a new growth driver in Lilly’s central nervous system pipeline if results are positive.

The main treatment is brenipatide, also known as LY3537031, given as a shot under the skin plus standard care drugs. The control group gets a placebo shot plus the same standard care, so any difference in outcomes can be tied to brenipatide itself.

The study is interventional and randomized, meaning people are assigned by chance to brenipatide or placebo. It is double blind and parallel arm, so neither patients nor doctors know who gets what, and groups are treated at the same time to compare safety and benefit.

The trial includes a one month screening phase, up to 12 months of treatment, and about two months of follow up, so each participant may be involved for around 15 months. The study was first submitted on 6 February 2026 and last updated on 12 February 2026, signaling that planning is current even though recruitment has not yet started.

For investors, this update adds another mid stage asset to Lilly’s long term story beyond obesity and diabetes. Success could give LLY a new schizophrenia product in a market now shaped by incumbents like Johnson & Johnson and Otsuka, boosting sentiment on its neuroscience portfolio while trial risk and long timelines remain key watch points.

The RENEW-Scz-1 study of brenipatide in schizophrenia is active in planning and updated, with further details available on the ClinicalTrials portal.

To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.